Skip to main content

Skin Lesion

0
Pipeline Programs
3
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Orlucent
OrlucentCA - Los Gatos
3 programs
Diagnostic TestN/A1 trial
MDSN/A1 trial
Melanoma Detection System -MDSN/A1 trial
Active Trials
NCT03535077Completed186Est. Dec 2022
NCT02193581Completed50Est. Dec 2017
NCT03109327Completed250Est. Oct 2020
Apollo Therapeutics
Apollo TherapeuticsUK - Cambridge
2 programs
ApolloVue S100 Image SystemN/A
Cellular resolution full-field optical coherence tomographyN/A1 trial
Active Trials
NCT05068310Recruiting200Est. Feb 2025
Pulse Biosciences
Pulse BiosciencesCA - Hayward
2 programs
CellFX SystemN/A1 trial
Nano-Pulse Stimulation DeviceN/A1 trial
Active Trials
NCT04539886Completed60Est. Nov 2021
NCT03612570Completed72Est. Nov 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Apollo TherapeuticsCellular resolution full-field optical coherence tomography
Pulse BiosciencesCellFX System
Pulse BiosciencesNano-Pulse Stimulation Device
OrlucentMelanoma Detection System -MDS
OrlucentDiagnostic Test
OrlucentMDS

Clinical Trials (6)

Total enrollment: 818 patients across 6 trials

NCT05068310Apollo TherapeuticsCellular resolution full-field optical coherence tomography

Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors

Start: Oct 2021Est. completion: Feb 2025200 patients
N/ARecruiting
NCT04539886Pulse BiosciencesCellFX System

Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions

Start: Sep 2020Est. completion: Nov 202160 patients
N/ACompleted
NCT03612570Pulse BiosciencesNano-Pulse Stimulation Device

Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia

Start: Jun 2018Est. completion: Nov 201872 patients
N/ACompleted
NCT03109327OrlucentMelanoma Detection System -MDS

Investigating the Clinical Utility of the MDS

Start: Apr 2018Est. completion: Oct 2020250 patients
N/ACompleted
NCT03535077OrlucentDiagnostic Test

Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging)

Start: Jan 2018Est. completion: Dec 2022186 patients
N/ACompleted
NCT02193581OrlucentMDS

Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging

Start: Aug 2017Est. completion: Dec 201750 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 818 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.